ProMIS Neurosciences Inc PMN

Any Idea Why?...

[Mole101]

ISSUER:

ProMIS Neurosciences Inc. Principal Jurisdiction - Ontario

 

  Preliminary Short Form Prospectus dated November 26, 2020 Withdrawn on March 5, 2021

PROJECT NUMBER:

3141885

OSC NOTICE TO PUBLIC

 

[Gbathat]

Mole, not sure if this is good (i.e., not needed anymore) or bad (i.e., something fell through or was contested as untrue)  I am not very famiiar with how these filings and un-filings work.   The company has been quiet for a bit.  Perhaps we'll get an update on things this month. Good luck to you.

[M101]

Elliot gambled on news before the awful fall financing, and now he's done the same with the spring rally that never materialized. Withdrawing one prospectus filing is most likely only a prelude to filing another with even worse terms as Elliot has bet yet again on aducanumab news, this time in June. Any exec with an ounce of integrity would look at this situation and either change the

[TopBroker]

You are correct M101 this so called CEO is thinking of himself and not his shareholders. For a small biotech with limited cash flow to pay not one but two executives is total negligence. Your shareholders AGM is coming up and you need to elect a new Director to clean up this mess and not one appointed by your Chairman and CEO. 

[Gbathat]

perhaps the aducanumab approval speculation becoming more optimistic is providing better leverage for management and the shareholders.  Just saying...

[Zoomie1999]

Optimism for the non-selective approach seems unlikely given concerns about overall performance of both Biogen's Aducanumab and Lilly's Donanemab.  I think door now wide open to finally try Promis' SELECTIVE targeting hypothesis via PMN-310.  Not sure this team can get that done. Therefore, partnership or sale of the "technology" to Biogen or Lilly may be our best

[retiredcop]

Neither.company has expressed any interesting buying pmn science....if any one does it will be a company that had a failure in their science or a company that sees that lilly and Biogen.are.going to.be the only ones in the market that is.worth billions...that desire.to get.into the market with someone.elses science will be the factor...it.could be as simple as joint.venture on the clinicals with

[farmerjane]

RC, how do you know neither company has expressed interest?

[retiredcop]

Because they would have already done it and cancelled the programs they are still putting millions of $$$$ into.        

[M101]

Hard to imagine a project team jumping horses after a "success", however qualified, or that the execs above them would force that decision.  Failure is what we need, but not too much and not too little: Goldstein's goldilocks zone. 

[farmerjane]

Poor answer!!

[M101]

Yeah well, if the corporate world worked on objective merit over politics Gene and Elliot would be long gone.     

[M101]

Please develop this hypothesis wrt immediate cash flow.